Management of hypertensive patients with ischemic heart disease and the role of a fixed-dose combination of telmisartan and metoprolol: a physician-based research survey
DOI:
https://doi.org/10.18203/2349-3933.ijam20231071Keywords:
Hypertension, Ischemic heart disease, Telmisartan, Metoprolol, Cardiovascular events, Angiotensin receptor blocker, Beta-blockerAbstract
Background: We aimed to understand the current practices of Indian practitioners in the management of hypertensive patients with ischemic heart disease.
Methods: A quantitative, cross-sectional, questionnaire-based survey involving 145 cardiologists and consulting physicians who each saw 10 patients with hypertension and IHD in their clinical practice was conducted. The questionnaire consisted of 35 questions divided into three sections on prevalence and treatment of hypertension and IHD and role of fixed-dose combinations in therapy.
Results: In all, 49.0% of physicians treated 25%-50% patients with hypertension and IHD in their routine practice, majority of whom were in the age group of 40-60 years regardless of gender. Telmisartan (97.0%) and metoprolol (86.0%) were the most preferred angiotensin receptor blocker (ARB) and beta-blocker, respectively, and 91.0% of physicians preferred a combination of metoprolol with telmisartan when monotherapy fails. In the opinion of the physicians, prevention of new cardiovascular events (63.0%) and improvement in quality of life (61.0%) were the leading benefits of telmisartan and metoprolol FDC, and all agreed that this FDC improves patient compliance and adherence to therapy. Furthermore, 97.0%, 90.0%, and 40.0% of physicians agreed/strongly agreed that the FDC could be prescribed to hypertensive patients with IHD, heart failure, and IHD and diabetes, respectively.
Conclusions: In this pan-India survey, it was observed that FDCs of telmisartan and metoprolol could help in improving blood pressure, heart rate, patient compliance, and adherence to therapy. Nevertheless, large-scale, prospectively designed studies are warranted to validate these findings.
References
Lu Y, Li J, Wang X, Cho J, Dorajoo SR, Feng M, et al. Characterizing dual combination therapy use in treatment escalation of hypertension: real-world evidence from multinational cohorts. MedRxiv. 2021;2:1-31.
MacDonald T, George J. Home blood pressure monitoring. Eur Cardiol. 2015;10:95-101.
Agbor-Etang BB, Setaro JF. Management of hypertension in patients with ischemic heart disease. Current Cardiol Rep. 2015;17:1-7.
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-3104.
Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383:1899-911.
Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American heart association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation. 2007;115:2761-88.
Shiga T, Kasanuki H, Hagiwara N, Sumiyoshi T, Honda T, Haze K, et al. Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function. Blood Press. 2010;19:359-65.
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127-248.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;38:982-1004.
Anthoine E, Moret L, Regnault A, Sébille V, Hardouin JB. Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes. 2014;12:176.
Špinar J. Hypertension and ischemic heart disease. Cor et Vasa. 2012;54:e433-8.
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67.
Lawes CM, Bennett DA, Lewington S, Rodgers A. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med. 2002;2: 355-68.
Jadhav U, Tiwaskar M, Khan A, Kalmath BC, Ponde CK, Sawhney J, et al. Hypertension in young adults in India: Perspectives and therapeutic options amongst clinician's in a cross-sectional observational study. J Assoc Physicians India. 2021;69:11-2.
Olafiranye O, Zizi F, Brimah P, Jean-Louis G, Makaryus AN, McFarlane S, et al. Management of hypertension among patients with coronary heart disease. Int J Hypertens. 2011;2011: 653903.
Telmisartan. Available at: https://pubchem.ncbi. nlm.nih.gov/compound/Telmisartan. Accessed on 24 April 2022.
